Sarepta Therapeutics Earnings Preview

Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Sarepta Therapeutics will report an earnings per share (EPS) of $-1.18.

Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here’s what investors need to know before the announcement.

Analysts estimate that Sarepta Therapeutics will report an earnings per share (EPS) of $-1.18.

Sarepta Therapeutics bulls will hope to hear the company to announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Historical Earnings Performance

Last quarter the company beat EPS by $0.71, which was followed by a 1.46% drop in the share price the next day.

Here’s a look at Sarepta Therapeutics’s past performance and the resulting price change:

Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021
EPS Estimate -1.27 -1.13 -1.89 -1.29
EPS Actual -0.56 -0.77 -0.19 -1.52
Price Change % -1.46% 4.66% 0.51% 16.36%

eps graph

Stock Performance

Shares of Sarepta Therapeutics were trading at $92.95 as of July 29. Over the last 52-week period, shares are up 33.2%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

To track all earnings releases for Sarepta Therapeutics visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Investors Cheer Upwork’s Q4 Performance, Stock Gains On Strong Guidance

Upwork reported quarterly earnings of 20 cents per share which beat the analyst consensus estimate of 17 cents by 17.65%. The company reported quarterly sales of $183.9 million, beating the analyst consensus estimate of $178.16 million by 3.22% and representing a 13.91% increase over sales of $161.44 million from the same period last year.

UPWK